Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
Status:
Completed
Trial end date:
2015-03-13
Target enrollment:
Participant gender:
Summary
This study is to examine the hypothesis that administration of RDEA3170 to Japanese patients
with gout or asymptomatic hyperuricemia in doses of 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg
once daily, respectively will result in greater reduction of sUA compared to placebo.